MedTrace Logo

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

NCT00297362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 344

Last updated 2012-03-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Galantamine hydrobromide

247 patients with diagnosed mild to moderate Alzheimer disease.

Sponsors & Collaborators

  • Janssen Cilag Pharmaceutica S.A.C.I., Greece

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Pharmaceutica S.A.C.I. Clinical Trial · Janssen-Cilag Pharmaceutica S.A.C.I.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2005-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297362 on ClinicalTrials.gov